Chonluten

What it is. Chonluten is a tripeptide described as derived from bronchial epithelial cells, one of the organ-specific short peptides characterised by Khavinson's group from 1973 onwards and originally isolated from animal tissues [1][2].

The one study, and why it is better than most. A group at the University "G. d'Annunzio" in Chieti-Pescara, collaborating with the St Petersburg institute, tested five of these peptides - Epitalon, Vilon, Thymogen, Thymalin and Chonluten - on THP-1 cells, a human monocytic leukaemia line that differentiates into macrophages. The findings:

• All five modulated proliferative patterns and increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases.
• Chonluten specifically inhibited TNF production by monocytes exposed to bacterial lipopolysaccharide, which the authors connect to TNF tolerance.
• All five inhibited LPS-stimulated TNF and IL-6 expression in terminally differentiated cells.
• Peptide-treated monocytes showed reduced adhesion to LPS-activated endothelial cells.

The authors conclude the peptides act as natural inducers of TNF tolerance in monocytes and as anti-inflammatory molecules [1].

This is worth distinguishing from most of the programme's output. It uses a standard human cell line, standard inflammatory readouts, and involves investigators outside the originating institute. It is still cell culture, and the effect described - reduced TNF and IL-6 after LPS - is one that a great many substances produce.

What does not exist. Any animal study specific to chonluten in the indexed literature. Any human trial. Any pharmacokinetic data. Any published sequence in the sources available for this entry, which is why none is stated here.

The mechanism proposed in the THP-1 study is induction of TNF tolerance - the state in which monocytes previously exposed to a stimulus respond to a subsequent LPS challenge with less TNF release. Combined with the reduction in IL-6 and in endothelial adhesion, this describes a general damping of monocyte pro-inflammatory activation [1].

That is a different framing from the rest of the family's literature, which is mostly about chromatin and gene expression [3][4]. The two are not incompatible - transcriptional changes could produce cytokine changes - but no study has connected them for this peptide.

The lung designation is not supported by anything in the mechanism. Chonluten is described as derived from bronchial epithelial cells [1], and the only functional work is in a monocytic line. Nothing demonstrates tropism for airway tissue.

Supplied as a lyophilised powder. No route, dose or formulation for use in an organism has been published, and no sequence is stated in the sources available for this entry.

No safety data of any kind exist: no toxicology, no animal study, no human exposure report.

The one mechanistic observation with a safety bearing runs in an ambiguous direction. Inducing TNF tolerance and damping monocyte activation is anti-inflammatory, and it is also immunosuppressive - TNF tolerance is a feature of sepsis-associated immunoparalysis, which is a state associated with secondary infection. Nothing in the published work examines whether the effect would be beneficial or harmful in a living animal, and no study has looked.

The absence of published harm here reflects the absence of anyone looking, not a safety record.

No interaction studies exist. Chonluten was tested alongside four other Khavinson peptides in the same experiments, as parallel comparisons rather than combinations [1].